SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use alternative lengthening of telomeres
Neuro-Oncology · 01.04.2026 · 28 (4) · 895-910
DOI: 10.1093/neuonc/noaf300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 10.01.2026. Verfasst von Alexandrea Brown und 16 weiteren Autor:innen. Beteiligte Einrichtung: The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham. Hauptthemen laut MEDLINE: DNA Helicases, Telomere Homeostasis, X-linked Nuclear Protein, Brain Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, The Preston Robert Tisch Brain Tumor Center.
Abstract (Originalsprache)
Background
Approximately 10% of cancers achieve replicative immortality through a telomerase-independent mechanism of telomere maintenance, termed Alternative Lengthening of Telomeres (ALT). ALT is particularly prevalent in certain subtypes of malignant gliomas, such as IDH-mutant astrocytoma and pediatric glioblastoma, and frequently co-occurs with ATRX (ATRX chromatin remodeler) inactivating mutations. Although ALT is an adaptive mechanism through which cancer cells achieve proliferative immortality, the elevated levels of replication stress observed in ALT tumors constitute a potential therapeutic vulnerability.
Methods
Leveraging CRISPR/Cas9 screening data from the Cancer Dependency Mapping Project, coupled with patient-derived cell lines and xenografts, we identified SMARCAL1 as a novel synthetic lethal vulnerability in ATRX-deficient glioma models that engage ALT. Using complementary molecular assays for DNA damage, telomere maintenance, and telomeric replication stress, we define the mechanisms underlying cytotoxicity induced by SMARCAL1 depletion in ALT-positive glioma cells.
Results
Our data demonstrate the annealing helicase SMARCAL1 is a highly specific synthetical lethal vulnerability in cancers that use ALT. SMARCAL1 localizes to ALT-associated PML (Promyelocytic leukemia protein) bodies in ALT-positive glioma cell lines, including IDH-mutant astrocytomas. SMARCAL1 depletion, via doxycycline-induced RNAi, led to a hyperactivation of the ALT phenotype, high levels of DNA double-strand breaks in G2 phase, and cell death via mitotic catastrophe. In mice bearing intracranial xenografts derived from high-grade IDH-mutant astrocytoma, inducible SMARCAL1 depletion prolonged animal survival.
Conclusions
Our findings demonstrate that the molecular processes orchestrating ALT-mediated telomere maintenance constitute a targetable synthetic lethal vulnerability that can be exploited by SMARCAL1 inhibition, thus supporting the future development of small molecule inhibitors of SMARCAL1 as anti-cancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham.
- Department of Neurosurgery, Duke University Medical Center, Durham.
- Department of Pathology, Duke University Medical Center, Durham.
- Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham.
ORCID-Profile: Justin T Low, Zachary J Reitman, Matthew S Waitkus
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- The Preston Robert Tisch Brain Tumor Center
- Uncle Kory Foundation Seed
- Duke Brain Tumor
- NIH HHS
- NIH
Zitieren
APA
Brown, A., Strickland, L. M., Erman, E. N., Pirozzi, C. J., Low, J. T., Diplas, B. H., Gibson, E., Shobande, M., Khambati, T., Krylova, M., Liu, H., McLendon, R. E., Reitman, Z. J., Keir, S. T., Zou, L., Ashley, D. M., & Waitkus, M. S. (2026). SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use alternative lengthening of telomeres. Neuro-Oncology, 28(4), 895-910. https://doi.org/10.1093/neuonc/noaf300
Vancouver
Brown A, Strickland LM, Erman EN, Pirozzi CJ, Low JT, Diplas BH, et al. SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use alternative lengthening of telomeres. Neuro-Oncology. 2026;28(4):895-910. doi:10.1093/neuonc/noaf300
BibTeX
@article{Brown2026,
author = {Brown, Alexandrea and Strickland, Laura M and Erman, Elise N and Pirozzi, Christopher J and Low, Justin T and Diplas, Bill H and Gibson, Emiley and Shobande, Mariah and Khambati, Taher and Krylova, Marharyta and Liu, Heng and McLendon, Roger E and Reitman, Zachary J and Keir, Stephen T and Zou, Lee and Ashley, David M and Waitkus, Matthew S},
title = {SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use alternative lengthening of telomeres},
journal = {Neuro-Oncology},
year = {2026},
volume = {28},
number = {4},
pages = {895--910},
doi = {10.1093/neuonc/noaf300}
}
EUVIMED